ClinicalTrials.gg

Program

dezandrodeg

Also written as “BMS-986365” and “CC-94676”.

Its studies are mostly in Prostatic Neoplasms, led by Bristol-Myers Squibb.

Furthest: phase 3, since Dec 17, 20245 company-led studies, 1 open or runningNext primary completion: Sep 12, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb51 open or runningphase 3since Dec 17, 2024May 29, 2020Sep 12, 2027phase 3 · NCT06764485

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04428788 · 131 enrolled · United States
  2. May 13, 20242 phase 1 studiesNCT06417229, NCT06433505
  3. Dec 17, 2024Phase 3 study in Prostatic NeoplasmsNCT06764485 · 960 enrolled · United States, Argentina, Australia and more
  4. Nov 17, 2025Phase 1 study in Healthy VolunteersNCT07242781 · 22 enrolled · United States

Ahead

  1. Sep 12, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06764485

TargetBeta

AR →read by rule
“An orally bioavailable androgen receptor (AR) degrader, ”NCIt, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07242781Healthy Volunteers · United States1TerminatedApr 9, 202622
NCT06764485Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingSep 12, 2027960
NCT06433505Healthy Volunteers · United States1CompletedFeb 14, 202524
NCT06417229Healthy Participants · United States1CompletedFeb 19, 2025102
NCT04428788Prostatic Neoplasms · United States1CompletedOct 28, 2025131

How it is read

Names in the registry

  • “BMS-986365”, 4 entries
  • “CC-94676”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.